Nasdaq Ipsc News Today

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among […]

Century Therapeutics (NASDAQ:IPSC – Get Free Report) and Athira Pharma (NASDAQ:ATHA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk. Valuation and Earnings This table compares Century […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has received an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among […]

- Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA ...

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price […]

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given an average rating of “Moderate Buy” by the eight ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective […]

Gladius Capital Management LP purchased a new position in Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 7,730 shares of the company’s stock, valued at approximately $27,000. A number of other institutional investors and hedge […]

Century Therapeutics (NASDAQ:IPSC – Get Free Report) had its price target reduced by research analysts at HC Wainwright from $17.00 to $13.00 in a research report issued to clients and investors on Thursday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 364.29% […]